鼠抗人肝癌单抗Hab_(18)—葡聚糖—阿霉素结合物在荷瘤裸鼠体内的放免定位及导向治疗的实验研究

In vivo Radioimmunograph and Targeting Therapy Mice Bearing Human Hepatocellular Carcinoma by Murine MAb-Hab 18-DEX-ADM Conjugate

本实验制备了鼠抗人肝癌单克隆抗体Hab_18—葡聚糖—阿霉素导向结合物,放免显像证实该结合物在荷人肝癌裸鼠体内能选择性地定位于人肝癌局部;对荷瘤鼠的毒理学实验中相同剂量的阿霉素组荷瘤鼠全部死亡,而导向结合物组全部存活;荷人肝癌裸鼠导向治疗结果表明:该结合物能有效地抑制人肝癌的生长,导向治疗组肿块较治疗前缩小.实验结果提示:Hab_18—DEX—ADM结合物对人肝癌有较好的导向治疗作用.其抗癌效果优于单纯ADM,而毒副作用却明显低于单纯ADM,有可能成为一种肝癌导向药物.

ADM was linked covalently to the murine MAb Habl8 specific for human hepatocellular carcinoma via a Dextran bonding. The antigen-binding capacity of the Habl8 in the conjugate was well preserved. Habl8 in the conjugate can specifically bind to target tumor cells on slides. The radioimmuneimaging ability of the conjugate labelled with Iodine-125 in the nude mice bearing human hepatocellular carcinoma indicated that the conjugate was well localized in the locus of the hepatocellular carcinoma. In the targeting therapy with the conjugate on nude mice bearing human hepatocellular carcinoma, the application of the Habl8-DEX-ADM conjugate effectively inhibited the growth of the hepatoma. The size of the tumors after targeting therapy was smaller than before. Whereas the size of the tumor remained unchanged in the group given ADM alone. The toxic effect of the HaB18-DEX-ADM conjugate to the host was far less than that of free ADM. These results suggest that the Habl8-DEX-ADM conjugate has a better effect against human hepatocellular carcinoma.